A compound capable of increasing interleukin-10 (IL-10) production for use in the treatment of inflammatory diseases, especially Th-1 mediated inflammatory diseases. The preferred compounds that are capable of increasing interleukin-10 production are a range of related 1-phenyl-2-amino ethanol, ethanal and ethane derivatives, especially Bupropion and its metabolites, most preferably erythro-2-hydrobupropion (R,S-hydrobupropion) denoted herein as BC1053. The preferred Th-1 mediated inflammatory diseases are systemic in nature and include psoriatic arthritis, psoriasis, Crohn s disease, ulcerative colitis, influenza, including pandemic flu, respiratory disorders such as respiratory syncitial virus (RSV), cystic fibrosis, herpes, asthma and allergies, sepsis and septic shock, bacterial pneumonia, bacterial meningitis, dengue fever, Type-1 diabetes, endometriosis, prostatitis, uveitis, uterine ripening, age-related macular degeneration, arthritic swelling, multiple sclerosis (MS), most preferably inflammatory bowel disease (IBD), arthritic swelling and rheumatoid arthritis (RA).
